

Frequent p16 CpG island hypermethylation in primary remnant gastric cancer suggesting an independent carcinogenic pathway

AYA MINO¹, NAOYOSHI ONODA^{1,2}, MASAKAZU YASHIRO¹, MAKOTO AYA¹, ICHIRO FUJIWARA¹,
NAOSHI KUBO¹, TETSUJI SAWADA¹, MASAICHI OHIRA¹, YASUYUKI KATO¹ and KOSEI HIRAKAWA¹

Departments of ¹Surgical Oncology and ²Oncology Institute of Geriatrics and
Medical Science, Osaka City University Graduate School of Medicine, Japan

Received August 18, 2005; Accepted October 11, 2005

Abstract. Cancer found in the post-operative remnant stomach includes both newly developed cancer after surgery for benign-disease (PRC) and metachronous multiple cancer (MRC). Differences in the carcinogenic pathway between PRC and MRC have been suspected from clinical studies. However, no study has demonstrated the difference in molecular alteration between these diseases. P16 is inactivated predominantly by epigenetic change, rather than genetic alteration. We analyzed the methylation status and protein expression of the p16 gene in cancers of the remnant stomach. Eleven lesions of PRC, 24 lesions of MRC and corresponding non-cancerous tissue, as well as 13 primary gastric cancer (PC) lesions were examined. DNA was extracted by the micro-dissection method from paraffin-embedded surgical specimens. The methylation status of the promoter CpG island of the p16 gene was examined by using a methylation-specific polymerase chain reaction technique. To detect protein expression, immunohistochemical staining was employed. p16 promoter hypermethylation was observed more often in remnant gastric cancer than in PC. A significantly more frequent hypermethylation in the p16 gene was found in PRC (64%) than in MRC (21%) or PC (23%). Moreover, a significant correlation was found between p16 promoter hypermethylation and diminishment of protein expression in cancers of the remnant stomach. Silencing of the p16 gene by methylation of its promoter CpG island was suggested as a unique molecular mechanism in the carcinogenesis of PRC compared with MRC or PC.

Introduction

Cancer found in the post-operative remnant stomach includes both newly developed cancer after surgery for benign disease,

and metachronous multiple cancer after primary gastric cancer surgery. Many former studies have demonstrated the clinical characteristics of these cancers found in the remnant stomach. Newly developed 'primary' remnant gastric cancer after surgery for benign disease (PRC) is often found in the stump of the remnant stomach after a long interval from the initial surgery (more than 20 years). The frequency of PRC has been reported to be around 1-3% (1) and the remnant stomach after distal gastrectomy is thought to be an organ at high risk of cancer development. Reflux of intestinal juices (2-4), de-nervation (5), and changes in bacterial inhabitation (6) have been reported as causative factors of cancer development in the remnant stomach. In contrast, cancer in the remnant stomach after primary gastric cancer surgery (or MRC, metachronous multiple remnant gastric cancer) is often found in the non-stump area after a shorter interval from the initial surgery than PRC (<10 years) (7). The involvement of *Helicobacter pylori* infection and chronic atrophic gastritis (8,9) on the carcinogenesis of MRC has been suggested, just as in primary gastric cancer (PC). Therefore, PRC and MRC have been suggested to have different characteristics and carcinogenic pathways, though both cancers develop in the remnant stomach.

Although several differences in the clinical features or the possible etiologies between PRC and MRC have been demonstrated as above, no molecular background has been able to display the difference of the two different types of cancer in the remnant stomach. Furthermore, several important genes, including p53 (10), bcl-2 (11), APC (12), or k-ras (13), have been found to demonstrate no unique alterations in remnant gastric cancer compared with PC. Our recent study (14) has suggested that genetic instability is more commonly found in remnant gastric cancer than PC. Moreover, the most recent report has indicated an accumulation of RUNX3 hypermethylation at the anastomotic mucosa of the remnant stomach (15). These results indicate that an abnormality in gene maintenance or epigenetic change rather than the alteration of a key gene might play a critical role in the mechanism of the carcinogenic pathway in the remnant stomach.

P16 is a tumor suppressor gene which maps to 9p21 and functions as an inhibitor of cyclin D-dependent protein kinases. P16 protein binds to cyclin-dependent kinase 4 (CDK4) and CDK6 (CDK6), and induces G1-phase arrest in the molecular machinery of the cell cycle by interfering with

Correspondence to: Dr Naoyoshi Onoda, Department of Oncology, Institute of Geriatrics and Medical Science, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan
E-mail: nonoda@med.osaka-cu.ac.jp

Key words: p16 gene methylation, remnant gastric cancer, carcinogenic pathway

Table I. Clinicopathological characteristics of the patients.

Clinical features	PRC (n=11)	MRC (n=24)	p-value
Age (mean)	69.8	67.0	n.s.
Sex (male/female)	9/2	21/3	n.s.
Location (stump/other) ^a	7/4	16/ 8	n.s.
pN (0/1-4)	7/4	5/16 ^b	n.s.
PStage (0,1/2-4)	6/5	12/12	n.s.
Interval from the initial surgery (mean; years)	(27.3)	(7.1)	<0.001
(-10/<10 years)	0/11	19/5	
Histological type (well/poor)	8/3	12/12	n.s.
Reconstruction method (BI/BII)	6/5	15/9	n.s.

^aStump included both anastomosis and suture line; ^bpN status at surgery was unknown in 3 cases. Well, well-differentiated adenocarcinoma included papillary and tubular carcinoma; Poor, poorly differentiated adenocarcinoma included poorly differentiated, mucinous and signet-ring cell carcinoma.

binary cyclin D-CDK4 complexes (16). Loss of p16 or its transcripts breaks down the regulatory mechanism of the cell cycle; thus, p16 plays a role as a tumor suppressor gene. Inactivation of p16 is one of the most commonly observed abnormalities in human cancers (17). P16 is inactivated by a combination of genetic or epigenetic alterations. Rather than genetic alterations, epigenetic change may be the predominant mechanism associated with the loss of p16 function in sporadic carcinoma (18).

This study was undertaken to determine the involvement of epigenetic change in the carcinogenic pathway of the remnant stomach by investigating p16 promoter CpG island hypermethylation in remnant gastric cancer and non-cancerous tissue, and to analyze the relationship between methylation status, p16 protein expression, and the clinicopathological features of remnant gastric cancer, including both PRC and MRC.

Materials and methods

Patients. Surgically resected specimens from 35 cases with cancer in the remnant stomach were analyzed. Eleven of these patients had undergone initial distal gastrectomy because of benign disease (PRC: primary remnant gastric cancer). Twenty-four had undergone curative surgery because of primary gastric cancer (MRC: metachronous multiple gastric cancer). The curability at initial surgery for the MRC cases was confirmed by pathological review of the specimens at the initial surgery. Total remnant gastrectomy was performed for these remnant gastric cancers from 1986 to 2004 at Osaka City University Hospital. The clinical and pathological features of the patients are summarized in Table I. The interval between surgeries was significantly longer in cases with PRC than




Figure 1. Representative results of the methylation-specific polymerase chain reaction. C and N indicate cancerous and non-cancerous tissue, respectively. M and U below the PCR products indicate the primers used for amplification; M represents primers for methylated and U for unmethylated p16 gene promoter CpG island, respectively. Both the 151-kb band indicating unmethylated p16 promoter CpG island and a 150-kb PCR product of methylated p16 products were found in the positive control lanes. At least one of the methylated or unmethylated products was clearly found in all samples examined. Bisulfite modified CpGenome™ Universal methylated DNA (Chemicon, Temecula, CA) was used as a DNA template for control of the methylated p16 gene. SM, size marker (50-bp DNA ladder).

Table II. Frequencies of p16 gene methylation.

	No.	Hyper- methylation	(%)	p-value
Non-cancerous tissue	48	3	(6.3)	<0.01 ^a
Primary gastric cancer	13	1	(7.7)	
Remnant gastric cancer	35	2	(5.7)	
Cancerous tissue	48	15	(31.3)	n.s. ^b
Primary gastric cancer	13	3	(23.1)	
Remnant gastric cancer	35	12	(34.3)	

^aSignificantly less frequent compared with cancerous tissue; ^bNo significant difference was found compared with remnant gastric cancer.

with MRC. Otherwise, no difference in the clinicopathological features was found between PRC and MRC. Thirteen cases of PC were also analyzed as a control. For each tumor, non-cancerous gastric mucosa without severe metaplasia, apart from the cancerous lesion, was available as an internal control.

Methylation-specific polymerase chain reaction (MSP). Samples for DNA extraction were obtained by the micro dissection method from formalin-embedded samples of both cancerous and non-cancerous tissues. Using hematoxylin-stained sections of 10 μ m thick, the tissue was scraped by a scalpel. Digestion was performed in proteinase K buffer (Gibco, Gaithersburg, MD), pH 8.1 at 55°C for 7 days. Proteinase K was inactivated by boiling for 8 min. The samples were rapidly cooled, and the DNA was stored at 4°C.

Extracted DNA was modified by sodium bisulfite to determine the methylation status by MSP (16). Polymerase chain reactions were performed in 10 μ l of reaction buffer containing 1 μ l 10X buffer (Applied Biosystems, Warrington, UK), 0.5 μ M deoxynucleotide triphosphates (Applied Biosystems), 5 μ M each primer, 0.5 μ l (20 ng/l) of extracted DNA, and 0.5 U Ampli Taq polymerase (Applied Biosystems). PCR amplification was carried out in a thermal cycler using the following conditions: 95°C for 5 min for a hot start; then 45

Factors	PRC		MRC	
	No.	Methylated (%)	No.	Methylated (%)
Sex				
Male	9	6 (66.7)	21	4 (19.0)
Female	2	1 (50.0)	3	1 (33.3)
Age				
<70	5	2 (40.0)	14	4 (28.6)
<71	6	5 (83.3)	10	1 (10.0)
Location				
Stump	7	4 (57.2)	16	3 (18.8)
Other	4	3 (75.0)	8	2 (25.0)
Interval				
1-10	-	-	19	5 (26.3)
<10	11	7 (63.6)	5	0 (0)
Histological type				
Well diff.	8	4 (50.0)	12	4 (33.3)
Poorly diff.	3	3 (100)	12	1 (8.3)
Stage				
Early	6	4 (66.7)	12	3 (25.0)
Advanced	5	3 (60.0)	12	2 (16.6)
Lymph node metastasis				
Negative	7	4 (57.1)	14	4 (28.6)
Positive	4	3 (75.0)	7	1 (14.3)
Reconstruction				
B-I	6	5 (83.3)	15	2 (13.3)
B-II	5	2 (40.0)	9	3 (33.3)
Total	11	7 (63.6)	24	5 (20.8)

cycles of 95°C for 30 sec, 60°C for 60 sec, and 72°C for 50 sec; and finally, 72°C for 10 min for extension. The primers used were as follows: unmethylated p16^{INK4a} (5'-TTA TTA GAG GGT GGG GTG GAT TGT-3', 5'-CAA CCC CAA ACC ACA ACC ATA A-3') and methylated p16^{INK4a} (5'-TTA TTA GAG GGT GGG GCG GAT CGC-3', 5'-GAC CCC GAA CCG CGA CCG TAA-3') (19). The PCR products were electrophoresed on a 2.5% agarose gel and visualized using ethidium bromide staining to determine the methylation status.

Immunohistochemistry. The protein expression of p16 was determined using the immunohistochemical staining technique, as described previously (20). Briefly, 4-μm sliced sections of formalin-fixed paraffin-embedded tissue were deparaffinized and incubated with 0.3% hydrogen peroxide in methanol for 30 min. Slides were autoclaved at 105°C for 10 min in X10 target retrieval solution (Dako, Carpinteria, CA) for antigen retrieval. After blocking to reduce non-specific antibody binding with normal rabbit serum, a 1:100 dilution of a mouse




Figure 2. The frequency of p16 methylation found in cancerous (closed bars) and non-cancerous (open bars) tissues according to the patients' background. Remarkably, more frequent hypermethylation in the p16 gene promoter CpG island was found in cancerous tissue of PRC than of MRC ($p=0.01$) or PC ($p=0.04$). * $p<0.01$; ** $p<0.05$.

monoclonal antibody to human p16 (sc1661; Santa Cruz Biochemicals, Santa Cruz, CA) was applied at 4°C overnight, followed by three washes with PBS. The sections were incubated with secondary antibody and reacted with strept-avidin-biotin peroxidase reagent (Histofine SAB-PO (M) kit, Nichirei Co., Tokyo, Japan). Finally, diaminobenzidine and 1% hydrogen peroxidase were applied as chromogen and counterstained with hematoxylin and eosin. Normal tissue without severe atrophy adjacent to the tumor was used as a positive control for p16 immunoreactivity. Positive nuclear stains in less than 50% of the cancer cells was considered to be a diminishment in expression.

Statistics. Statistical analyses were performed using Mann-Whitney's U-test and the Kruskal-Wallis test. A p -value <0.05 was considered significant.

Results

We were able to demonstrate a good reproducible result from MSP, as shown in Fig. 1. At least one of the methylated or unmethylated products was clearly found in all of the samples examined. Samples with a detectable methylated product were determined as positive for hypermethylation. Methylation of the p16 gene was found in only 2 of 35 (5.7%) non-cancerous tissues. In contrast, methylation was found in 12 of 35 (34.3%) cancerous tissues, and was significantly more frequent than that of non-cancerous tissues (Table II). P16 promoter hypermethylation was more commonly found in cancer of the remnant stomach (including PRC and MRC) than PC, although the difference was not significant. When the clinicopathological backgrounds of the cancer in the remnant stomach were compared, no significant correlation was found between p16 promoter methylation status and age, gender, pathological stage, histological type, reconstruction method, or tumor location (Table III). However, remarkably more frequent hypermethylation in the p16 gene was found in PRC (7/11; 63.6%) than in MRC (5/24; 20.8%, $p=0.01$) or PC (3/13; 23.1%, $p=0.04$) (Fig. 2).




Figure 3. Representative results of the immunohistochemical analysis of P16 expression in remnant gastric carcinomas (original magnification, x40). P16 immunoreactivity localized in the nucleus was universally observed in p16 unmethylated cancerous tissue (A, case 3). Markedly diminished p16 immunoreactivity was observed in methylation-positive cancer cells in solid arrangement (B, case 7).

Table IV. Correlation between p16 protein expression and p16 hypermethylation in cases with RGC.

p16 Methylation	p16 Immunostaining		Total
	Positive (%)	Diminished (%)	
Negative	19 (82.6)	4 (17.4)	23
Positive	1 (8.3)	11 (91.7)	12
Total	20 (57.1)	15 (42.9)	35

In non-tumoral mucosa, every specimen was positive for P16 immunoreactivity. No loss in p16 immunoreactivity was found in any of the cases. Diminished immunoreactivity was found in 15 of 35 (42.9%) cancerous tissues. P16 expression was diminished in 7 of 11 (63.6%) cancerous lesions in PRC, 8 of 24 (33.3%) in MRC and 4 of 13 (30.8%) in PC. The diminishment in P16 expression was more often found in cases with PRC than MRC and PC, although the difference was not statistically significant (Fig. 3). Eleven of 12 (91.7%) cancerous tissues of the remnant stomach with hypermethylation showed diminished p16 protein expression. In contrast, 19 of 23 (82.6%) cancerous tissues without p16 methylation expressed the p16 protein. Thus, a significant correlation between p16 promoter methylation and diminished protein expression was found ($p < 0.004$) (Table IV).

Discussion

The remnant stomach after partial gastrectomy is known as one of the critical organs at high risk of cancer development. Former epidemiological reports from European countries have suggested that the risk for developing cancer is statistically higher in the remnant stomach than that in the non-operative stomach (1,21,22). Although some studies carried out in places with high contraction rates for gastric cancer, such as Japan, have found no elevation in the cancer risk in the remnant stomach (23), typical PRC at the stump of the remnant stomach

was often encountered similar to in European countries. Moreover, many experimental and clinical studies have suggested the existence of unique carcinogenic mechanisms at the stump area of the remnant stomach after distal gastrectomy. The influence of reflux of the duodenal juice on cancer development at anastomosis of the remnant stomach in animal models is well known (4). We have also observed the acceleration of glandular hypertrophy and cellular proliferation at anastomosis in clinical samples more predominantly in Billroth II type reconstruction, where reflux is more commonly found than in Billroth I type reconstruction (24-26). Kaminishi *et al* have reported that surgical denervation impairs the defense mechanism in the mucosa at the stump of the remnant stomach, leading to tumor development in experimental models (5). Therefore, PRC has been suggested to form a more independent entity than PC of the non-operated stomach. Still, little is known about the molecular backgrounds of PRC and no unique genetic alterations have been identified. In the present study, we investigated the p16 promoter methylation status in cancers of the remnant stomach and found a statistically higher rate of hypermethylation in PRC than in MRC or PC. This epigenetic change clearly led to a down-regulation of P16 protein expression in cancer and may be a unique molecular background of cancer development in the remnant stomach after surgery for benign disease.

The influences of epigenetic change in cancer development have been demonstrated well in inflammation-related cancers, including ulcerative colitis (27) and Barrett's esophagus (28). Chronic inflammation has also been reported to be involved in the process of gastric carcinogenesis (29). Although we found no remarkable accumulation of p16 methylation in the non-cancerous mucosa of the remnant stomach, the influences of chronic inflammation on the aberrant methylation of p16 in the stomach mucosa have been suggested (30). Former studies have found promoter CpG island hypermethylation, including that of p16, in precancerous tissues (31-34) and have suggested that methylation tends to accumulate throughout multi-step gastric carcinogenesis. In the present study, we did not use mucosa with severe inflammation or with obvious metaplasia as 'non-cancerous tissue', which may explain why we could

SPANDIDOS PUBLICATIONS frequent p16 methylation in the 'non-cancerous' in the present study. The involvement of p16 gene silencing in remnant gastritis, such as stomal gastritis and intestinal metaplasia, should be investigated to clarify the involvement of this epigenetic change in possible precursors of PRC.

Hypermethylation of p16 has been reported in PC (32,35). The frequency in p16 promoter methylation in former studies has varied from 25 to 43%. We compared PRC, MRC, and PC in the same series and confirmed a diminishment of p16 expression in methylated samples, and found that down regulation of p16 by methylation is a common molecular abnormality in PRC. The P16 gene regulates the cell cycle, and its dysfunction causes an acceleration of cell growth (36). Thus, a silencing of p16 function by promoter methylation might be a unique molecular mechanism in PRC that could trigger cancer development and/or progression. Furthermore, our results indicate that MRC and PC have a similar molecular background and are different from PRC. Similarities in MRC and PC have been suggested by many clinical investigations. We can therefore conclude that PRC and MRC are different entities, based not only on their clinical features but also on their molecular background.

The conditions of the stomal portion of the remnant stomach may be regarded as suitable for frequent p16 methylation. Regurgitation of the duodenal juice, including bile and pancreatic juices with high pH, is known as the main causative factor of stomal gastritis. Chronic mucosal inflammation with stomal gastritis and subsequent induction of superoxide and nitric oxide are known as strong inducers of DNA methyltransferase (37,38). Moreover, p16 methylation is frequently reported in cholangiocarcinoma (39-42), suggesting a strong involvement of bile in aberrant methylation. We have also found that PRC has a higher rate of methylation in genes other than p16 compared with PC (preliminary data, not shown). Furthermore, in a recent report, Nakase *et al* demonstrated that the involvement of hypermethylation in RUNX3 correlates well with the existence of stomal gastritis in the remnant stomach (15). Although they found a clear tendency toward RUNX3 methylation in stomal gastritis, no difference was found in the frequency of methylation between PRC, MRC, and PC. In contrast, p16 methylation in non-cancerous tissue was not frequent in our series, but it differed in cancer in the remnant stomach. Methylation in DNA is known to occur in a gene-specific manner, and the sensitivity to methylation differs between genes (43). It therefore appears that epigenetic change may occur in genes step-by-step and independently to develop cancer. Furthermore, aberrant methylation is known to induce DNA instability (44). It is therefore worth investigating the correlation between methylation and genetic instability in stomal gastritis and PRC.

Based on the present results we suggest that there are different molecular pathways in carcinogenesis of the remnant stomach after surgery for benign disease compared with that after cancer surgery, as has been demonstrated in many clinical investigations (7,26). Furthermore, as Klump has suggested (39), the promoter methylation status may be a candidate marker for diagnosis and for clinically unapparent neoplastic alterations in patients with remnant stomach. Further study is necessary to investigate the status of aberrant methylation in

stomal gastritis in the remnant stomach to clarify the clinical significance of the correlation between mucosal inflammation and carcinogenesis in the remnant stomach.

References

1. Viste A, Bjornestad E, Opheim P, Skarstein A, Thunold J, Hartveit F, Eide GE, Eide TJ and Soreide O: Risk of carcinoma following gastric operations for benign disease: a historical cohort study of 3470 patients. *Lancet* 2: 502-505, 1986.
2. Domell FL, Eriksson S, Mori H, Weisburger JH and Williamsam GM: Effect of bile acid gavage or vagotomy and pyloroplasty on gastrointestinal carcinogenesis. *Am J Surg* 142: 551-554, 1981.
3. Dewer P, Dixon MF and Jonjston D: Bile reflux and degree of gastritis in patients with gastric ulcer: before and after operation. *J Surg Res* 3: 277-284, 1984.
4. Miwa k, Hasegawa H, Fujimura T, Matsumoto H, Miyata R, Kosaka T, Miyazaki I and Hattori T: Duodenal reflux through the pylorus induces gastric adenocarcinoma in the rat. *Carcinogenesis* 13: 2313-2316, 1992.
5. Kaminishi M, Shimizu N, Shiomoyama S, Yamaguchi H, Ogawa T, Sakai S, Kuramoto S and Oohara T: Etiology of gastric remnant cancer with special reference to the effects of denervation of the gastric mucosa. *Cancer* 75: 1490-1496, 1995.
6. Domellof L, Reddy BS and Weinbeurger JH: Microflora and deconjugation of bile acids in alkaline reflux after partial gastrectomy. *Am J Surg* 140: 291-295, 1980.
7. Sowa M, Onoda N, Nakanishi I, Maeda K, Yoshikawa K, Kato Y and Chung YS: Early stage carcinoma of the gastric remnant in Japan. *Anticancer Res* 13: 1835-1838, 1993.
8. Onoda N, Maeda K, Sawada T, Wakasa K, Arakawa T and Hirakawa K: Prevalence of *Helicobacter pylori* infection in gastric remnant after distal gastrectomy for primary gastric cancer. *Gastric Cancer* 4: 87-92, 2001.
9. Onoda N, Katsuragi K, Sawada T, Maeda K, Mino A, Ohira M, Ishikawa T, Wakasa K and Hirakawa K: Efficacy of *Helicobacter pylori* eradication on the chronic mucosal inflammation of the remnant stomach after distal gastrectomy for early gastric cancer. *J Clin Exp Cancer Res* (In press).
10. Ochiai M, Matsubara T, Zhi LZ, Funabiki T, Sakurai Y, Hasegawa S, Imazu H and Suganuma M: Gastritis cystica polyposa associated with a gastric stump carcinoma, with special reference to cell kinetics and p53 gene aberrations. *Gastric Cancer* 3: 165-170, 2000.
11. Clarke MR, Safatle-Ribeiro AV, Ribeiro U, Sakai P and Reynolds JC: bcl-2 protein expression in gastric remnant mucosa and gastric cancer 15 or more years after partial gastrectomy. *Mod Pathol* 10: 1021-1027, 1997.
12. Fein M, Peters JH, Baril N, McGarvey M, Chandrasoma P, Shibata D, Laird PW and Skinner KA: Loss of function of Trp53, but not Apc, leads to the development of esophageal adenocarcinoma in mice with jejunoesophageal reflux. *J Surg Res* 83: 48-55, 1999.
13. Van Rees BP, Musler A, Caspers E, Drillenburger P, Craanen ME, Polkowski W, Chibowski D and Offerhaus GJ: K-ras mutations in gastric stump carcinomas and in carcinomas from the non-operated stomach. *Hepatogastroenterology* 46: 2063-2068, 1999.
14. Aya M, Yashiro M, Nishioka N, Onoda N and Hirakawa K: Carcinogenesis in the remnant stomach following distal gastrectomy with Billroth II reconstruction is associated with high-level microsatellite instability. *Anticancer Res* (In press).
15. Nakase Y, Sakakura C, Miyagawa K, Kin S, Fukuda K, Yanagisawa A, Koide K, Morofuji N, Hosokawa Y, Shimomura K, Katsura K, Hagiwara A, Yamagishi H, Ito K and Ito Y: Frequent loss of RUNX3 gene expression in remnant stomach cancer and adjacent mucosa with special reference to topography. *Br J Cancer* 92: 562-569, 2005.
16. Serrano M, Hannon GJ and Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. *Nature* 366: 704-708, 1993.
17. Sherr CJ and Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. *Genes Dev* 9: 1149-1163, 1995.
18. Lee YY, Kang SH, Seo JY, Jung CW, Lee KU, Choe KJ, Kim BK, Kim NK, Koeffler HP and Bang YJ: Alterations of p16^{INK4A} and p15^{INK4B} genes in gastric carcinomas. *Cancer* 80: 1889-1896, 1997.

19. Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB: Methylation specific PCR: a novel PCR assay for methylation status of CpG islands. *Proc Natl Acad Sci USA* 93: 9821-9826, 1996.
20. Ogisawa K, Onoda N, Ishikawa T, Takenaka C, Inaba M, Ogawa Y and Chung KH: Establishment and characterization of OCUT-1, an undifferentiated thyroid cancer cell line expressing high level of telomerase. *J Surg Oncol* 80: 197-203, 2002.
21. Carvalho R, Milne AN, van Rees BP, Caspers E, Cirnes L, Figueiredo C, Offerhaus GJ and Weterman MA: Early-onset gastric carcinomas display molecular characteristics distinct from gastric carcinomas occurring at a later age. *J Pathol* 204: 75-83, 2004.
22. Toftgaard C: Gastric cancer after peptic ulcer surgery: a historic prospective cohort investigation. *Ann Surg* 210: 159-164, 1989.
23. Tokudome S: Risk of gastric remnant cancer in Japan. *Jpn J Cancer Res* 82: 871-872, 1991.
24. Sowa M, Nakanishi K, Chung YS, Kato Y, Kubo T, Fujimoto Y, Nishiwaki H, Yoshikawa K, Umeyama K, Kobayashi K and Otani S: Ornithine decarboxylase activity of the mucosa of the gastric remnant using endoscopic biopsy specimen, comparison between B-I and B-II. *Dig Endosc* 3: 201-205, 1991.
25. Sowa M, Chung YS, Fujimoto Y, Nishimura M, Kibo T, Maekawa H, Kato Y, Nishiwaki H, Yoshikawa K, Umeyama K and Kobayashi K: A histologic study of endoscopic biopsies of the gastric remnant mucosa following subtotal gastrectomy, with special reference to changes of the stomal mucosa. *Dig Endosc* 2: 169-175, 1990.
26. Onoda N, Nakanishi I, Chung YS, Maeda K, Nishimura S, Sato S, Kubo T, Kato Y, Yoshikawa K, Matsui-Yuasa I, Otani S and Sowa M: Analysis of cell proliferation in endoscopically biopsied specimens of stomal mucosa of the gastric remnant. *Dig Endosc* 6: 176-180, 1994.
27. Hsieh CJ, Klump B, Holzmann K, Borchard F, Gregor M and Porschen R: Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. *Cancer Res* 58: 3942-3945, 1998.
28. Eads CA, Lord RV, Kurumboor SK, Wickramasinghe K, Skinner ML, Long TI, Peters JH, DeMeester TR, Danenberg KD, Danenberg PV, Laird PW and Skinner KA: Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. *Cancer Res* 60: 5021-5026, 2000.
29. Correa P: Human gastric carcinogenesis: a multistep and multifactorial process - First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. *Cancer Res* 52: 6735-6740, 1992.
30. Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakiuchi H, Hinoda Y and Imai K: Distinct methylation pattern and microsatellite instability in sporadic gastric cancer. *Int J Cancer* 83: 309-313, 1999.
31. Toyota M, Ahuja N, Suzuki H, Itoh F, Ohe-Toyota M, Imai K, Baylin SB and Issa JP: Aberrant methylation in gastric cancer associated with CpG island methylator phenotype. *Cancer Res* 59: 5438-5442, 1999.
32. Shim YH, Kang GH and Ro JY: Correlation of p16 hypermethylation with p16 protein loss in sporadic gastric carcinomas. *Lab Invest* 80: 689-695, 2000.
33. Tsujie M, Yamamoto H, Tomita N, Sugita Y, Ohue M, Sakita I, Tamaki Y, Sekimoto M, Doki Y, Inoue M, Matsuura N, Monden T, Shiozaki H and Monden M: Expression of tumor suppressor gene p16(INK4) products in primary gastric cancer. *Oncology* 58: 126-136, 2000.
34. Kang GH, Lee HJ, Hwang KS, Lee S, Kim JH and Kim JS: Aberrant CpG island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation. *Am J Pathol* 163: 1551-1556, 2003.
35. Leung WK, Yu J, Ng EK, To KF, Ma PK, Lee TL, Go MY, Chung SC and Sung JJ: Concurrent hypermethylation of multiple tumor-related genes in gastric carcinoma and adjacent normal tissues. *Cancer* 91: 2294-2301, 2001.
36. Song SH, Jong HS, Choi HH, Kand SH, Ryu MH, Kim NK, Kim WH and Bang YJ: Methylation of specific CpG sites in the promoter region could significantly down-regulate p16ink4a expression in gastric adenocarcinoma. *Int J Cancer* 87: 236-240, 2000.
37. Ohshima H: Genetic and epigenetic damage induced by reactive nitrogen species: implications in carcinogenesis. *Toxicol Lett* 140-141: 99-104, 2003.
38. Hmadacha A, Bedoya FJ, Sobrino F and Pintado E: Methylation-dependent gene silencing induced by interleukin 1beta via nitric oxide production. *J Exp Med* 190: 1595-1604, 1999.
39. Klump B, Hsieh CJ, Dette S, Holzmann K, Kiebetlich R, Jung M, Sinn U, Ortner M, Porschen R and Gregor M: Promoter methylation of INK4a/ARF as detected in bile-significance for the differential diagnosis in biliary disease. *Clin Cancer Res* 9: 1773-1778, 2003.
40. Rashid A: Cellular and molecular biology of biliary tract cancers. *Surg Oncol Clin N Am* 11: 995-1009, 2002.
41. Lee S, Kim WH, Jung HY, Yang MH and Kang GH: Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma. *Am J Pathol* 161: 1015-1022, 2002.
42. Tannapfel A, Sommerer F, Benicke M, Weinans L, Katalinic A, Geissler F, Uhlmann D, Hauss J and Wittekind C: Genetic and epigenetic alterations of the INK4a-ARF pathway in cholangiocarcinoma. *J Pathol* 197: 624-631, 2002.
43. Esteller M, Corn PG, Baylin SB and Herman JG: A gene hypermethylation profile of human cancer. *Cancer Res* 61: 3225-3229, 2001.
44. Jones PA and Gonzalgo ML: Altered DNA methylation and genome instability: a new pathway to cancer? *Proc Natl Acad Sci USA* 94: 2103-2105, 1997.